Summary
Background
This Bococizumab biosimilar antibody uses the same variable regions as the therapeutic antibody Bococizumab, making it ideal for research use. Bococizumab is a humanized IgG2 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a secreted serine protease that regulates plasma LDL cholesterol by controlling LDL receptor (LDLR) recycling. PCSK9 binds LDLR on hepatocytes and directs the receptor to lysosomal degradation, reducing LDLR surface expression and increasing circulating LDL cholesterol levels. By binding PCSK9 with high affinity, Bococizumab prevents its interaction with LDLR, thereby increasing receptor availability and enhancing LDL clearance. Although therapeutic development of Bococizumab was discontinued due to immunogenicity and variable LDL-lowering responses, it remains a valuable research tool for studying PCSK9–LDLR biology, lipid metabolism, hepatocyte receptor regulation, and mechanisms underlying antibody-mediated PCSK9 inhibition. This Bococizumab biosimilar is well suited for investigating cardiovascular disease pathways, metabolic regulation, and therapeutic strategies targeting the PCSK9–LDLR axis.
